摘要
目的观察胸/腹腔灌注维拉帕米及化疗药物的疗效和毒副作用。方法57例恶性胸/腹腔积液,胸腹腔联合灌注维拉帕米及化疗药物,1个周期治疗后评价疗效及毒副反应。结果胸/腹腔灌注的有效率(CR+PR)为89.5%,其中胸水的总有效率(CR+PR)为88.9%,腹水的总有效率(CR+PR)为90.0%。Ⅰ度胃肠道反应(42.1%),2例II度消化道反应,灌注部位轻度疼痛(22.8%),发热(19.3%),白细胞下降(10.5%)。结论维拉帕米联合化疗药物胸/腹腔灌注可以提高胸腹水治疗的有效率。
Aim To observe the therapeutic effect of therapeutic alliance of verapamil and chemotherapeutics splanchnocoel perfusion. Methods 57 hydrothorax and seroperitoneum were splanchonocoel perfused with verapamil and chemotherapeutics,therapeutic effect evaluated after 2 courses of treatment. Results The general effective rate of splanchnocoel perfusion was 89.5% , including hydrothorax 88.9% and seropelitoneum 90.0%. The incidence of untoward reaction were nausea and vomiting 42.1% , mild pain 22.8% ,fever 19. 3% ,leucocyte decrease 10.5%. Conclusion Therapeutic alliance of verapamil and chemotherapeutics splanchnocoel perfusion could increase therapeutic effective rate of hydrothorax and seoperitoneum.
出处
《安徽医药》
CAS
2010年第4期453-455,共3页
Anhui Medical and Pharmaceutical Journal
关键词
胸/腹水
维拉帕米
P-糖蛋白
多药耐药
灌注化疗
hydrothorax/seroperitoneum
verapamil
P-glycoprotein
multiple drug resistance
chemotherapeutic splanchnocoel perfusion
